Safety and Effectiveness Study of The Swedish Adjustable Gastric Band (SAGB) in the Treatment of Morbid Obesity

Obesity, Morbid Clinical Trial

Official title:

A Single-Arm, Multi-Center Study of the Safety and Effectiveness of The Swedish Adjustable Gastric Band (SAGB) in the Treatment of Morbid Obesity

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT00166205
• Other study ID #: CI-02-0006
• Status: Completed
• Phase: Phase 3
• First received: September 9, 2005
• Last updated: August 3, 2015
• Start date: June 2003
• Est. completion date: December 2006

Study information

• Verified date: August 2015
• Source: Ethicon Endo-Surgery
• Contact: n/a
• Is FDA regulated: No
• Health authority: United States: Food and Drug Administration
• Study type: Interventional

Clinical Trial Summary

The purpose of this study is to determine whether the Swedish Adjustable Gastric Band (SAGB) is safe, and effective in achieving weight loss in patients with Morbid Obesity.

Description:

Surgical treatment of morbidly obese patients is considered a reasonable option for achieving weight loss when more conservative measures, such as diet and exercise have failed. Not only can weight loss be achieved, but also reduction / resolution of a patient's co-morbidities associated with excess weight. Adjustable gastric banding provides a less invasive, reversible bariatric surgery option. The SAGB has been commercially available outside the United States for this indication since 1996. Commercial availability has led to extensive literature supporting the safety and effectiveness of the SAGB. Given the available literature, a prospective, single arm, multicenter, study in a heterogeneous population of morbidly obese subjects in the U.S. is being conducted.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 276
• Est. completion date: December 2006
• Accepts healthy volunteers: No
• Gender: Both
• Age group: 18 Years to 60 Years

Eligibility

Inclusion Criteria:

• Able to comprehend, follow and give signed informed consent;

• 18 to 60 years of age (inclusive);

• Five year history of morbid obesity;

• Body Mass Index (BMI) >40 kg/m2 and <55 kg/m2, or BMI >35 kg/m2 and <40 kg/m2 with one or more significant medical conditions related to obesity (co-morbid conditions of type 2 diabetes, hyperlipidemia, obstructive sleep apnea, hypertension, metabolic syndrome, or osteoarthritis of the hip or knee) for which the subject is being treated, and which are generally expected to be improved, reversed, or resolved by weight loss.

• 100 lbs. overweight or 1.5 times ideal weight;

• Documented failure of conservative, non-surgical means of weight reduction within one year prior to the Screening Visit, including failure of supervised diet, exercise and or behavior modification programs, and pharmacologic therapy;

• Willing to commit to significant lifestyle changes that include diet, eating, and exercise habits for the duration of the clinical trial;

• Able to commit to long-term follow-up, including band adjustment visits:

• Living within the contiguous U.S. and is within a 100 mile radius of the study center;

• Absence of significant psychopathology that could limit the subject's ability to understand the procedure, comply with medical, surgical, and/or behavioral recommendations, as documented during screening assessment;

• Agrees to refrain from any type of reconstructive surgery that would affect body weight such as abdominal lipoplasty or liposuction, mammoplasty, or removal of excess skin for the follow-up period following SAGB placement; and

• Candidate for surgical weight loss intervention (i.e., meets accepted health criteria for major surgery).

Exclusion Criteria:

• Women of childbearing potential who are not practicing an effective method of birth control or who are pregnant or lactating;

• Previous malabsorptive or restrictive procedures performed for the treatment of obesity;

• Documented history of drug and/or alcohol abuse within two years of the Screening Visit;

• History of impaired mental status including, but not limited to active substance abuse, a history of schizophrenia, borderline personality disorder, uncontrolled depression, suicidal attempts within the past two years or current suicidal tendencies or ideations;

• Presence of any of the following medical conditions;

• Inflammatory diseases of the gastrointestinal tract, including severe intractable esophagitis, gastric ulceration, duodenal ulceration, or specific inflammation such as Crohn's disease that have been active within the past 10 years;

• Congenital or acquired anomalies of the GI tract, including atresias or stenosis,

• Severe cardiopulmonary disease or other serious organic disease that makes the subject a high-risk surgical candidate;

• Uncontrolled hypertension;

• Portal Hypertension;

• Uncontrolled Diabetes Mellitus;

• Chronic or acute upper gastrointestinal bleeding conditions, e.g. gastric or esophageal varices;

• Cirrhosis;

• Congenital or acquired intestinal telangiectasia;

• Esophageal or gastric disorders including severe preoperative reflux, dysmotility, or Barrett's Esophagus;

• Presence of hiatal hernia;

• Prior surgery of the foregut including hiatal hernia repair or prior gastric surgery;

• Chronic pancreatitis;

• Immunocompromised such as that resulting from chronic oral steroid use, chemotherapeutic agents, or immune deficiency disorders;

• Conditions that, in the opinion of the investigator, may jeopardize the subject's well-being and/or the soundness of this clinical study;

• History or presence of pre-existing autoimmune connective tissue disease, i.e., systemic lupus erythematosus or scleroderma;

• Presence of terminal illness with life expectancy <5 years;

• Use of prescription or over the counter weight reduction medications or supplements within one month of the Screening Visit and for the duration of study participation;

• Acute or chronic infection (localized or systemic);

• Known or suspected allergy to silicone or other materials contained in the Swedish Adjustable Gastric Band;

• History of intolerance to implanted devices;

• Not ambulatory; and

• Participation in another clinical trial within 8 weeks of the Screening Visit and for the duration of this trial.

Study Design

Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment

Related Conditions & MeSH terms

• Obesity
• Obesity, Morbid

Intervention

Device:
• Swedish Adjustable Gastric Band
Long term implantable device.

Locations

Country	Name	City	State
United States	Hamilton Medical Center - Weight Management	Dalton	Georgia
United States	CAREMAX Surgical, P.C.	East Patchogue	New York
United States	US Bariatrics	Ft. Lauderdale	Florida
United States	Dartmouth-Hitchcock Medical Center	Lebanon	New Hampshire
United States	Cedars-Sinai Medical Center	Los Angeles	California
United States	Advanced Surgical Institute at Mercy Hospital	Miami	Florida
United States	University of Minnesota	Minneapolis	Minnesota
United States	Weight Management Center	New Orleans	Louisiana
United States	St. Luke's-Roosevelt Hospital Center	New York	New York
United States	Surgical Consultants of San Antonio	San Antonio	Texas
United States	Scripps Clinic Medical Group	San Diego	California
United States	Cleveland Clinic Florida	Weston	Florida

Sponsors (1)

Lead Sponsor	Collaborator
Ethicon Endo-Surgery

Country where clinical trial is conducted

United States, 

References & Publications (2)

Phillips E, Ponce J, Cunneen SA, Bhoyrul S, Gomez E, Ikramuddin S, Jacobs M, Kipnes M, Martin L, Marema RT, Pilcher J, Rosenthal R, Rubenstein R, Teixeira J, Trus T, Zundel N. Safety and effectiveness of Realize adjustable gastric band: 3-year prospective — View Citation

Phillips E; SAGB Study Group. Design and demography of the United States Swedish Adjustable Gastric Band trial: a 3-year prospective study. Surg Obes Relat Dis. 2008 May-Jun;4(3 Suppl):S63-72. doi: 10.1016/j.soard.2008.04.009. — View Citation

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Percent of Subjects Who Had Adverse Events With the Swedish Adjustable Gastric Band (SAGB)	Percent of device-related adverse events (AEs) and device malfunctions occurring in subjects implanted with the Swedish Adjustable Gastric Band from baseline throughout the three-year post-operative period.	3 years	Yes
Primary	Percent Excess Weight Loss	Percent Excess Weight Loss (%EWL) with the SAGB at three years post operatively minus baseline.	3 Years Post Operative	No
Secondary	Changes in Excess Body Weight (EBW)	Changes in excess body weight at 3-years post-operative minus baseline excess weight. Excess weight is computed as baseline weight minus Ideal weight. Ideal weight as provided in the 1983 Metropolitan Life Height and Weight Table using the upper limit of the midpoint range.	3 years	No
Secondary	Changes in Body Mass Index (BMI)	Changes in Body Mass Index (BMI) at three-years post-operative minus baseline.	3 years	No
Secondary	Change in Absolute Weight	Absolute weight loss as measured on a standardized Tanita Scale (used at all sites) at three-years post-operative minus baseline.	3 years	No
Secondary	Changes in Quality of Life (QOL) Measures	Changes in QOL measures at three-years post-operative minus baseline. SF-36 scores from 0-100 with higher scores representing better QOL.	3 years	No
Secondary	Changes in Glycosylated Hemoglobin (HbA1c)	Changes in glycosylated hemoglobin (HbA1c), from baseline to three-years post-operative.	3 years	No
Secondary	Number of All Adverse Events of Subjects Implanted With the SAGB	The evaluation of all Adverse Events of subjects implanted with the Swedish Adjustable Gastric Band throughout the three-year post-operative period (related to device and unrelated to device).	3 Years	Yes
Secondary	Changes in High Density Lipoproteins (HDL)	Changes in High Density Lipoproteins (HDL), at three-years post-operative minus baseline.	3 year	No
Secondary	Changes in Low Density Lipoproteins (LDL)	Changes in Low Density Lipoproteins (LDL), at three-years post-operative minus baseline.	3 years	No
Secondary	Changes in Total Cholesterol	Changes in Total Cholesterol, at three-years post-operative minus baseline.	3 years	No

External Links

•   PubMed Abstract 3-yr Results
•   PubMed Abstract Design